Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today reports financial results for the quarter ending September 30, 2022, and updates from the Company's key pipeline developments, business operations and upcoming milestones.
"Rocket had a remarkable third quarter highlighted by significant progress in our Phase 1 clinical trial for Danon Disease, with positive early findings demonstrating RP-A501 was generally well tolerated with evidence of positive treatment effect and improvement of the natural course of the disease in pediatric patients with up to nine months follow-up. Additionally, we observed continued, durable robust activity in adults with up to 36 months follow-up," said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma. "As previously announced, we reached an understanding with the FDA on chemistry, manufacturing and controls (CMC) requirements to start AAV cGMP manufacturing at our in-house facility as well as potency assay plans for a Phase 2 pivotal study. We are now laser focused on advancing Phase 2 pivotal study design and endpoint selection with FDA feedback expected this quarter."
Dr. Shah continued, "In the third quarter, we also announced the expected acquisition of Renovacor which aims to further solidify our leadership in AAV-based cardiac gene therapy. By combining Rocket's clinical, regulatory, and chemistry, manufacturing and control expertise with Renovacor's compelling preclinical research in BAG3-associated dilated cardiomyopathy and early assets, we look forward to advancing precision gene therapies even further to address the significant unmet need of patients with genetically driven cardiac diseases."
"Based on the strong results presented across our Leukocyte Adhesion Deficiency-I (LAD-I) and Fanconi Anemia (FA) lentiviral gene therapy programs to date, we remain on track towards our first regulatory filings in 2023 ? LAD-I in the first half and FA in the second half ? and expect to present data on both programs at ASH in December," said Dr. Shah. "Regarding our Pyruvate Kinase Deficiency (PKD) program, we also expect to share updated data from both adult patients at ASH. Both pediatric patients in the study have been enrolled. We now anticipate a Phase 1 update in the first half of 2023 and initiation of the Phase 2 pivotal trial in 2023."
Dr. Shah continued, "Finally, our exceptional third quarter progress was capped off by an extension of our cash runway into the second half of 2024 following an equity raise with net proceeds of $108.2 million. Taken together, I am very proud of our continued progress at Rocket and look forward to the final push towards another successful year in our pursuit of gene therapy cures for patients and their loved ones facing these devastating, life-threatening genetic diseases."
Key Pipeline and Operational Updates
Upcoming Investor Conferences
Third Quarter Financial Results
Financial Guidance
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare childhood disorders. The Company's platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rocket's first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a devastating, pediatric heart failure condition. For more information about Rocket, please visit www.rocketpharma.com.
Rocket Cautionary Statement Regarding Forward-Looking Statements
Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding its guidance for 2022 in light of COVID-19, the pending acquisition of Renovacor, the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), and Danon Disease, the expected timing and data readouts of Rocket's ongoing and planned clinical trials, the expected timing and outcome of Rocket's regulatory interactions and planned submissions, Rocket's plans for the advancement of its Danon Disease program and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's ability to monitor the impact of COVID-19 on its business operations and take steps to ensure the safety of patients, families and employees, the interest from patients and families for participation in each of Rocket's ongoing trials, our expectations regarding the delays and impact of COVID-19 on clinical sites, patient enrollment, trial timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's Annual Report on Form 10-K for the year ended December 31, 2021, filed February 28, 2022 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||
|
|
|
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
Revenue | $ |
- |
|
$ |
- |
|
$ |
- |
|
$ |
- |
|
||||||
Operating expenses: | ||||||||||||||||||
Research and development |
|
43,383 |
|
|
39,621 |
|
|
115,533 |
|
|
92,459 |
|
||||||
General and administrative |
|
15,105 |
|
|
10,025 |
|
|
39,728 |
|
|
30,456 |
|
||||||
Total operating expenses |
|
58,488 |
|
|
49,646 |
|
|
155,261 |
|
|
122,915 |
|
||||||
Loss from operations |
|
(58,488 |
) |
|
(49,646 |
) |
|
(155,261 |
) |
|
(122,915 |
) |
||||||
Research and development incentives |
|
- |
|
|
- |
|
|
- |
|
|
500 |
|
||||||
Interest expense |
|
(465 |
) |
|
(534 |
) |
|
(1,395 |
) |
|
(2,514 |
) |
||||||
Interest and other income, net |
|
1,353 |
|
|
806 |
|
|
2,644 |
|
|
2,218 |
|
||||||
Amortization of premium on investments - net |
|
(156 |
) |
|
(744 |
) |
|
(1,128 |
) |
|
(2,111 |
) |
||||||
Net loss | $ |
(57,756 |
) |
$ |
(50,118 |
) |
$ |
(155,140 |
) |
$ |
(124,822 |
) |
||||||
Net loss per share - basic and diluted | $ |
(0.87 |
) |
$ |
(0.79 |
) |
$ |
(2.37 |
) |
$ |
(1.99 |
) |
||||||
Weighted-average common shares outstanding - basic and diluted |
|
66,215,535 |
|
|
63,825,429 |
|
|
65,406,844 |
|
|
62,828,601 |
|
September 30, |
December 31, |
|||||||
|
2022 |
|
2021 |
|||||
Cash, cash equivalents, and investments | $ |
306,534 |
$ |
388,740 |
||||
Total assets |
|
417,265 |
|
497,020 |
||||
Total liabilities |
|
49,952 |
|
42,296 |
||||
Total stockholders' equity |
|
367,313 |
|
454,724 |
These press releases may also interest you
|